Immix Biopharma, Inc. IMMX
We take great care to ensure that the data presented and summarized in this overview for Immix Biopharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMMX
View all-
Bleichroeder LP New York, NY850KShares$3.58 Million0.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA730KShares$3.07 Million0.0% of portfolio
-
Lynwood Capital Management Inc.405KShares$1.71 Million11.13% of portfolio
-
Geode Capital Management, LLC Boston, MA187KShares$789,2730.0% of portfolio
-
Morgan Stanley New York, NY121KShares$508,0200.0% of portfolio
-
State Street Corp Boston, MA99KShares$416,6210.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA90.9KShares$382,5120.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il89.8KShares$378,0490.0% of portfolio
-
Northern Trust Corp Chicago, IL89.3KShares$375,9570.0% of portfolio
-
United Capital Financial Advisers, LLC Newport Beach, CA70.7KShares$297,5710.0% of portfolio
Latest Institutional Activity in IMMX
Top Purchases
Top Sells
About IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Insider Transactions at IMMX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2025
|
Gabriel S Morris CFO |
BUY
Open market or private purchase
|
Direct |
770
+0.26%
|
$4,620
$6.58 P/Share
|
|
Dec 10
2025
|
Ilya M Rachman CEO and Chairman |
BUY
Open market or private purchase
|
Direct |
746
+0.07%
|
$4,476
$6.67 P/Share
|
|
Dec 08
2025
|
Gabriel S Morris CFO |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
156,000
+26.77%
|
$0
$0.8 P/Share
|
|
Sep 17
2025
|
Ilya M Rachman CEO and Chairman |
BUY
Open market or private purchase
|
Direct |
2,500
+0.22%
|
$5,000
$2.02 P/Share
|
|
Sep 16
2025
|
Gabriel S Morris CFO |
BUY
Open market or private purchase
|
Direct |
2,600
+0.89%
|
$2,600
$1.97 P/Share
|
|
Jun 18
2025
|
Gabriel S Morris CFO |
BUY
Open market or private purchase
|
Direct |
2,225
+0.77%
|
$4,450
$2.28 P/Share
|
|
Jun 18
2025
|
Ilya M Rachman CEO and Chairman |
BUY
Open market or private purchase
|
Direct |
2,178
+0.19%
|
$4,356
$2.29 P/Share
|
|
Dec 23
2024
|
Jason Hsu Director |
BUY
Open market or private purchase
|
Direct |
40,000
+4.29%
|
$80,000
$2.19 P/Share
|
|
Dec 20
2024
|
Jason Hsu Director |
BUY
Open market or private purchase
|
Direct |
7,700
+0.89%
|
$15,400
$2.17 P/Share
|
|
Aug 22
2024
|
Jason Hsu Director |
BUY
Open market or private purchase
|
Direct |
8,100
+0.95%
|
$16,200
$2.25 P/Share
|
|
Aug 21
2024
|
Jason Hsu Director |
BUY
Open market or private purchase
|
Direct |
15,000
+1.76%
|
$30,000
$2.23 P/Share
|
|
Aug 16
2024
|
Carey Ng Director |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$10,000
$1.86 P/Share
|
|
Jul 24
2024
|
Jason Hsu Director |
BUY
Open market or private purchase
|
Direct |
6,000
+0.72%
|
$12,000
$2.15 P/Share
|
|
Jul 18
2024
|
Jason Hsu Director |
BUY
Open market or private purchase
|
Direct |
3,200
+0.39%
|
$6,400
$2.07 P/Share
|
|
Jun 07
2024
|
Ilya M Rachman CEO and Chairman |
BUY
Open market or private purchase
|
Direct |
2,600
+0.23%
|
$5,200
$2.13 P/Share
|
|
Jun 07
2024
|
Gabriel S Morris CFO |
BUY
Open market or private purchase
|
Direct |
2,500
+0.87%
|
$5,000
$2.12 P/Share
|
|
Jun 04
2024
|
Ilya M Rachman CEO and Chairman |
BUY
Open market or private purchase
|
Direct |
3,300
+0.29%
|
$3,300
$1.81 P/Share
|
|
Jun 04
2024
|
Gabriel S Morris CFO |
BUY
Open market or private purchase
|
Direct |
3,300
+1.15%
|
$3,300
$1.81 P/Share
|
|
May 20
2024
|
Gabriel S Morris CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
48,282
+29.09%
|
-
|
|
May 20
2024
|
Gabriel S Morris CFO |
BUY
Grant, award, or other acquisition
|
Direct |
194,218
+40.95%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 11K shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 156K shares |